(2-amino-5-ethoxy-4-trifluoromethyl-phenyl)-carbamic acid tert.-butyl ester | 473537-75-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2-amino-5-ethoxy-4-trifluoromethyl-phenyl)-carbamic acid tert.-butyl ester
• 英文别名: (2-amino-5-ethoxy-4-trifluoromethyl-phenyl)-carbamic acid tert-butyl ester；Carbamic acid,n-[2-amino-5-ethoxy-4-(trifluoromethyl)phenyl]-,1,1-dimethylethyl ester；tert-butyl N-[2-amino-5-ethoxy-4-(trifluoromethyl)phenyl]carbamate
• CAS: 473537-75-6
• 化学式: C₁₄H₁₉F₃N₂O₃
• 分子量: 320.312
• InChiKey: UXKVDHBWXZINNK-UHFFFAOYSA-N

物化性质

• 沸点：
  349.6±42.0 °C(Predicted)
• 密度：
  1.257±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  73.6
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3-oxo-3-(3-[1,2,3]triazol-1-yl-phenyl)-propionic acid tert.-butyl ester 、 (2-amino-5-ethoxy-4-trifluoromethyl-phenyl)-carbamic acid tert.-butyl ester 以 甲苯 为溶剂， 生成 {5-ethoxy-2-[3-oxo-3-(3-[1,2,3]triazol-1-yl-phenyl)-propionylamino]-4-trifluoromethyl-phenyl}-carbamic acid tert.-butyl ester
  参考文献：
  名称：

  Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 3. New potent non-competitive metabotropic glutamate receptor 2/3 antagonists

  摘要：

  A series of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives was evaluated as non-competitive mGluR2/3 antagonists. Replacement of the (2-aryl)-ethynyl-moiety in 8-position with smaller less lipophilic substituents produced compounds inhibiting the binding of [3H]-LY354740 to rat mGluR2 with low nanomolar affinity and consistent functional effect at both mGluR2 and mGluR3. These compounds were able to reverse LY354740-mediated inhibition of field excitatory postsynaptic potentials in the rat dentate gyrus and in vivo activity could be demonstrated by reversal of the LY354740-induced hypoactivity in mice after oral administration. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.02.076
• 作为产物：
  描述：

  (5-ethoxy-2-nitro-4-trifluoromethyl-phenyl)-carbamic acid tert-butyl ester 在 palladium-carbon 作用下， 生成 (2-amino-5-ethoxy-4-trifluoromethyl-phenyl)-carbamic acid tert.-butyl ester
  参考文献：
  名称：

  Dihydro-benzo [b] [1,4] diazepin-2-one derivatives

  摘要：

  这项发明是一种二氢苯并[1,4]二氮杂环己-2-酮衍生物，其化学式如下所示：其中R1、R2、R3和Y的定义如规范中所述。该发明包括含有这些化合物的药物组合物，其制备方法以及通过给予化合物I或其药用可接受盐的有效剂量来治疗或预防急性和/或慢性神经系统疾病的方法。

  公开号：

  US20020198197A1

文献信息

• Dihydro-benzo [b] [1,4] diazepin-2-one derivatives
  申请人：——

  公开号：US20020198197A1

  公开（公告）日：2002-12-26

  This invention is a dihydro-benzo [b] [1,4] diazepin-2-one derivative of the formula 1 wherein R 1 , R 2 , R 3 and Y are as defined in the specification. The invention includes pharmaceutical compositions containing these compounds, a process for their preparation and a method of treatment or prevention of acute and/or chronic neurological disorders by administering an effective amount of the compound of formula I or a pharmaceuticall acceptable salt thereof.

  这项发明是一种二氢苯并[1,4]二氮杂环己-2-酮衍生物，其化学式如下所示：其中R1、R2、R3和Y的定义如规范中所述。该发明包括含有这些化合物的药物组合物，其制备方法以及通过给予化合物I或其药用可接受盐的有效剂量来治疗或预防急性和/或慢性神经系统疾病的方法。
• [EN] COMBINATION OF MGLUR2 ANTAGONIST AND ACHE INHIBITOR FOR TREATMENT OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS<br/>[FR] COMBINAISON D'ANTAGONISTE MGLUR2 ET D'INHIBITEUR ACHE DESTINEE AU TRAITEMENT DE TROUBLES NEUROLOGIQUES AIGUS ET/OU CHRONIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005014002A1

  公开（公告）日：2005-02-17

  The present invention relates to a method of treatment or prevention of acute and/or chronic neurological disorders, to a pharmaceutical composition comprising an inhibitor of acetylcholinesterase (AChE inhibitor) and a metabotropic Glutamate receptor 2 antagonist (mGluR2 antagonist), to the use of an AChE inhibitor and a mGluR2 antagonist in the preparation of a medicament, and. to kits comprising an AChE inhibitor and a mGluR2 antagonist.

  本发明涉及一种治疗或预防急性和/或慢性神经系统疾病的方法，涉及一种包含乙酰胆碱酯酶抑制剂（AChE抑制剂）和代谢型谷氨酸受体2拮抗剂（mGluR2拮抗剂）的药物组合物，涉及在制备药物中使用AChE抑制剂和mGluR2拮抗剂，以及包含AChE抑制剂和mGluR2拮抗剂的试剂盒。
• DIHYDRO-BENZO[B][1,4]DIAZEPIN-2-ONE SULFONAMIDE DERIVATIVES
  申请人：Gatti McArthur Silvia

  公开号：US20080261957A1

  公开（公告）日：2008-10-23

  The present invention relates to compounds of formula (I), a process for the manufacture thereof, their use for the preparation of medicaments for treating CNS disorders and pharmaceutical compositions containing them. Compounds of formula (I) are represented by general formula (I) wherein R 1 , R 2 , R 3 and R 4 are defined as in the specification.

  本发明涉及式(I)的化合物，其制备方法，它们用于制备用于治疗中枢神经系统疾病的药物以及含有它们的药物组合物。式(I)的化合物由通用式(I)表示，其中R1、R2、R3和R4如规范中定义。
• Dihydro-benzo &lsqb;B&rsqb; &lsqb;1,4&rsqb; diazepin-2-one derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06548495B2

  公开（公告）日：2003-04-15

  This invention is a dihydro-benzo[b][1,4]diazepin-2-one derivative of the formula wherein R1, R2, R3 and Y are as defined in the specification. The invention includes pharmaceutical compositions containing these compounds, a process for their preparation and a method of treatment or prevention of acute and/or chronic neurological disorders by administering an effective amount of the compound of formula I or a pharmaceuticall acceptable salt thereof.

  这项发明涉及一种二氢苯并[b][1,4]二氮杂烷-2-酮衍生物，其化学式中的R1、R2、R3和Y如规范中所定义。该发明包括含有这些化合物的药物组合物、其制备方法以及通过给予公式I化合物或其药学上可接受的盐的有效量来治疗或预防急性和/或慢性神经系统疾病的方法。
• Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists
  作者：Thomas J. Woltering、Jürgen Wichmann、Erwin Goetschi、Frédéric Knoflach、Theresa M. Ballard、Jörg Huwyler、Silvia Gatti

  DOI：10.1016/j.bmcl.2010.09.125

  日期：2010.12

  This study completes a series of papers devoted to the characterization of the non-competitive mGluR2/3 antagonist properties of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives with particular emphasis on derivatizations compatible with brain penetration and in vivo activity. Especially the compounds bearing a para-pyridine consistently showed in vivo activity in rat behavioral models after oral administration, for example, blockade of the mGluR2/3 agonist LY354740-induced hypoactivity and improvement of a working memory deficit induced either by LY354740 or scopolamine in the delayed match to position task (DMTP). Moreover, combination studies with a cholinesterase inhibitor show apparent synergistic effects on working memory impairment induced by scopolamine. (C) 2010 Elsevier Ltd. All rights reserved.